Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. Its clinical programs comprise ELVN-001, a small molecule kinase inhibitor which is in Phase 1 clinical trial to treat adults with chronic myeloid leukemia; and ELVN-002, a central nervous system (CNS) penetrant and irreversible human epidermal growth factor receptor 2 inhibitor that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer (NSCLC) and other HER2 mutant tumors. The company was founded in 2019 and is headquartered in Boulder, Colorado.
Metrics to compare | ELVN | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELVNPeersSector | |
|---|---|---|---|---|
P/E Ratio | −17.3x | −1.4x | −0.5x | |
PEG Ratio | −5.22 | −0.01 | 0.00 | |
Price/Book | 3.9x | 1.9x | 2.6x | |
Price / LTM Sales | - | 4.2x | 3.2x | |
Upside (Analyst Target) | 33.2% | 59.9% | 51.4% | |
Fair Value Upside | Unlock | 8.3% | 8.5% | Unlock |